JP Morgan Chase
DAWN

JP Morgan Chase’s Day One Biopharmaceuticals DAWN Stock Holding History

JP Morgan Chase’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.1M Buy
3,134,753
+3,091,223
+7,101% +$43.6M ﹤0.01% 1205
2025
Q4 		$406K Sell
43,530
-22,152
-34% -$185K ﹤0.01% 5162
2025
Q3 		$463K Sell
65,682
-23,420
-26% -$161K ﹤0.01% 5082
2025
Q2 		$579K Buy
89,102
+27,566
+45% +$190K ﹤0.01% 4697
2025
Q1 		$488K Buy
61,536
+1,109
+2% +$11.9K ﹤0.01% 4793
2024
Q4 		$766K Sell
60,427
-556
-0.9% -$7.74K ﹤0.01% 4801
2024
Q3 		$849K Buy
60,983
+530
+0.9% +$7.56K ﹤0.01% 4572
2024
Q2 		$833K Sell
60,453
-10,756
-15% -$157K ﹤0.01% 4384
2024
Q1 		$1.18M Sell
71,209
-33,587
-32% -$503K ﹤0.01% 4227
2023
Q4 		$1.53M Buy
104,796
+13,270
+14% +$161K ﹤0.01% 4029
2023
Q3 		$1.12M Buy
91,526
+23,942
+35% +$312K ﹤0.01% 3983
2023
Q2 		$807K Buy
67,584
+45,373
+204% +$593K ﹤0.01% 4208
2023
Q1 		$297K Sell
22,211
-49,795
-69% -$973K ﹤0.01% 4815
2022
Q4 		$1.55M Sell
72,006
-5,308
-7% -$109K ﹤0.01% 3753
2022
Q3 		$1.55M Buy
77,314
+60,799
+368% +$1.29M ﹤0.01% 3673
2022
Q2 		$295K Sell
16,515
-4,436
-21% -$45.8K ﹤0.01% 4867
2022
Q1 		$208K Sell
20,951
-31,009
-60% -$410K ﹤0.01% 5171
2021
Q4 		$875K Buy
51,960
+47,737
+1,130% +$981K ﹤0.01% 4488
2021
Q3 		$100K Buy
4,223
+4,169
+7,720% +$99.9K ﹤0.01% 5565
2021
Q2 		$1K Buy
+54
New +$1.13K ﹤0.01% 6238

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's DAWN Position: Q1 2026 in Review

JP Morgan Chase increased its Day One Biopharmaceuticals (DAWN) stake by 7,101% in Q1 2026, buying an estimated $43.6M and bringing the position to 3,134,753 shares worth $67.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

JP Morgan Chase first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • JP Morgan Chase held 3,134,753 shares of Day One Biopharmaceuticals worth $67.1M as of Q1 2026.
  • JP Morgan Chase bought 3,091,223 Day One Biopharmaceuticals shares in Q1 2026, an estimated $43.6M.
  • Day One Biopharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1205 holding.
  • JP Morgan Chase first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.